AP Sports SummaryBrief at 6:46 p.m. EST
Empowered Funds LLC lifted its holdings in Teck Resources Limited ( NYSE:TECK – Free Report ) (TSE:TECK) by 3.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,607 shares of the basic materials company’s stock after acquiring an additional 707 shares during the quarter. Empowered Funds LLC’s holdings in Teck Resources were worth $1,129,000 at the end of the most recent reporting period. Other large investors have also bought and sold shares of the company. Headlands Technologies LLC acquired a new position in Teck Resources in the second quarter worth $38,000. Eastern Bank acquired a new position in Teck Resources during the 3rd quarter worth about $39,000. Bruce G. Allen Investments LLC increased its position in Teck Resources by 77.4% in the 3rd quarter. Bruce G. Allen Investments LLC now owns 878 shares of the basic materials company’s stock valued at $46,000 after acquiring an additional 383 shares in the last quarter. Blue Trust Inc. increased its position in Teck Resources by 583.1% in the 2nd quarter. Blue Trust Inc. now owns 1,052 shares of the basic materials company’s stock valued at $48,000 after acquiring an additional 898 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV raised its stake in shares of Teck Resources by 69.7% in the third quarter. Massmutual Trust Co. FSB ADV now owns 996 shares of the basic materials company’s stock worth $52,000 after acquiring an additional 409 shares during the last quarter. 78.06% of the stock is currently owned by institutional investors. Teck Resources Trading Down 0.8 % TECK opened at $46.81 on Friday. The firm’s fifty day moving average is $48.89 and its two-hundred day moving average is $48.60. The firm has a market cap of $23.55 billion, a PE ratio of 70.74 and a beta of 1.04. Teck Resources Limited has a twelve month low of $35.25 and a twelve month high of $55.13. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.35 and a current ratio of 2.92. Teck Resources Cuts Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Friday, December 13th will be issued a dividend of $0.0895 per share. This represents a $0.36 annualized dividend and a dividend yield of 0.76%. The ex-dividend date of this dividend is Friday, December 13th. Teck Resources’s dividend payout ratio (DPR) is presently 56.06%. Analysts Set New Price Targets Several analysts have recently commented on the stock. Scotiabank increased their price target on shares of Teck Resources from $78.00 to $79.00 and gave the company a “sector outperform” rating in a research note on Tuesday, October 8th. UBS Group cut Teck Resources from a “buy” rating to a “neutral” rating in a research note on Monday, November 11th. JPMorgan Chase & Co. cut their price target on Teck Resources from $57.00 to $55.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Deutsche Bank Aktiengesellschaft lowered Teck Resources from a “buy” rating to a “hold” rating and set a $50.00 price objective for the company. in a research report on Friday, October 25th. Finally, Citigroup upgraded shares of Teck Resources to a “hold” rating in a research report on Wednesday, October 2nd. Five analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $65.29. View Our Latest Stock Analysis on Teck Resources Teck Resources Profile ( Free Report ) Teck Resources Limited engages in exploring for, acquiring, developing, and producing natural resources in Asia, Europe, and North America. The company operates through Steelmaking Coal, Copper, Zinc, and Energy segments. Its principal products include copper, zinc, steelmaking coal, and blended bitumen. Recommended Stories Receive News & Ratings for Teck Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teck Resources and related companies with MarketBeat.com's FREE daily email newsletter .
Trump, not yet in office, already a figure in global economic policyChuck Woolery, smooth-talking game show host of 'Love Connection' and 'Scrabble,' dies at 83The Iranian regime has “intensified” its secretive development of nuclear detonators at covert facilities, the National Council of Resistance of Iran (NCRI) revealed, citing intelligence that exposes alarming advancements in weaponization technologies. The National Council of Resistance of Iran (NCRI) issued a stark warning during a Thursday press conference, revealing the Islamic regime’s escalated efforts to advance nuclear weapon technologies. This includes significant developments at the METFAZ facility, a critical division of the Organization for Advanced Defense Research (SPND). According to the NCRI’s report , these efforts focus on nuclear detonators, specifically Exploding Bridgewire (EBW) devices, crucial for triggering nuclear explosions. The report highlights that METFAZ’s operations are centered at the newly renamed Meshkat Complex in Sanjarian, a heavily guarded site located roughly 25 miles east of Tehran. It further outlines that the facility is central to manufacturing high-explosive materials under the guise of oil industry research conducted by the Arvin Kimia Abzar company, which NCRI asserts is a covert front for military purposes. The prominent Iranian opposition group’s officials identified key figures in this program, including Saeed Borji, chairman of Arvin Kimia Abzar, and CEO Akbar Motallebizadeh. Both are high-ranking experts in SPND with extensive histories in nuclear weapons projects, including EBW detonators. Borji’s involvement with explosive technologies dates back to his training with Ukrainian scientist Vyacheslav V. Danilenko, highlighting international dimensions to Iran’s nuclear efforts. “Transparency is non-existent in the regime’s nuclear program,” said Alireza Jafarzadeh, Deputy Director of NCRI’s Washington Office, as he stressed the need for immediate International Atomic Energy Agency (IAEA) inspections of the Meshkat Complex and other critical sites. He elaborated: Specifically, I think the one area that we need to focus [on] is the nuclear weapons program of the regime. I think out of all the other various threats of the regime, whether it’s their proxies and their activities in the region, their warmongering, they have received major blows in those areas. The one area that they’re counting on– and it is crucial for the survival of the regime is their nuclear weapons program of Iran. And that’s where I think the focus should be. They’re more dangerous there than they have ever been. They will go head-on as they are doing. They may avoid taking some precautionary measures that they used to make because they feel like this is the last round. And that’s why I think everyone should be concerned, whether it is the capitals in Europe or right here in Washington. That’s where you want to focus. You wanna make sure that the Iran regime doesn’t get the bomb. He also warned of the regime’s secrecy and the proliferation of “unknown sites” that complicate oversight. “But, in reality, there’s so much unknown; there’s so many different unknown sites, that there is really only one sure way to end the threat of the nuclear weapons program of the Iran regime — and that’s ending the rule of the mullahs in Iran,” he added. The NCRI, which has been instrumental in exposing Iran’s clandestine nuclear activities for over two decades, first revealed the Natanz uranium enrichment site in 2002, leading to international inspections. Their latest revelations spotlight Iran’s continuing nuclear ambitions despite global sanctions and diplomatic efforts to curb weaponization. The SPND, established under the late Brigadier General Mohsen Fakhrizadeh, is central to these activities. Its subdivisions, including METFAZ, have systematically advanced weaponization components while evading oversight by the IAEA. During the press conference, the NCRI called for immediate action, including: IAEA Inspections: Unrestricted access to the Meshkat Complex and related facilities. Reinstatement of Sanctions: Use of the UN Security Council’s snapback mechanism to restore comprehensive sanctions on Iran. Increased Scrutiny of Weaponization: Focus on weaponization, not just uranium enrichment levels, in international negotiations. In a statement to Breitbart News, Jafarzadeh emphasized the secretive nature of Iran’s nuclear ambitions. “There is not a single instance where the Iranian regime has voluntarily come forward and said, ‘This is what we’re doing; this is our activity; this is our program.’ None of that. It has always been covert, and it will always remain covert,” he said. “However, the level of escalation we are witnessing, along with the resources they are now allocating, is a clear indication that they are intensifying their efforts.” “The regime is focusing on building a bomb as the only means for its survival,” he added. Soona Samsami, NCRI’s U.S. representative, emphasized the regime’s reliance on deception to obstruct verification efforts by the International Atomic Energy Agency (IAEA). “While global attention remains fixated on uranium enrichment levels, the Iranian regime is covertly advancing the weaponization aspect of its nuclear program,” she noted. Maryam Rajavi, NCRI’s President-elect, reiterated the importance of a non-nuclear Iran, emphasizing that regime change through internal resistance offers the only sustainable solution. The revelations underscore the urgent need for the international community to prevent the Iranian regime from acquiring nuclear weapons and address its longstanding policy of denial and deception. The events come as Israeli Prime Minister Benjamin Netanyahu urged Iranians to rise up against their government, amid reports of Israeli plans to target Iran’s nuclear program following the collapse of the Assad regime and its air defenses. Massive protests that erupted in Iran in 2022, have led to documented abuses by the regime, growing international criticism, and support for a democratic republic, highlighted by a bipartisan U.S. resolution endorsing Rajavi’s “Ten Point Plan” for a free, secular, and non-nuclear Iran. The NCRI has long warned that Iran — the largest state sponsor of terrorism worldwide — is witnessing a revolution “in the making,” with the Islamic Republic no longer capable of containing widespread dissent. In October, hundreds of prominent world leaders and legislators convened at the NCRI headquarters on the outskirts of Paris to attend the group’s 2024 Free Iran World Summit and express support for the organization’s efforts in support of a free Iran. Joshua Klein is a reporter for Breitbart News. Email him at jklein@breitbart.com. Follow him on Twitter @JoshuaKlein .
LISTEN: Bruce McAvaney on sacrifices, his biggest critic, what's nextDominant runs by Estwanik and Dailey in Hannover Re Half-Marathon
MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocations in primary human hepatocytes Metagenomi Adenine Base Editor (ABE) demonstrates no detectable translocations and no significant genomic base composition differences in primary T-cells EMERYVILLE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today presented a talk titled “Specific and efficient genome editing with metagenomics-derived tools for in vivo and ex vivo therapeutic applications” at the Nature Conference: RNA at the Bench and Bedside IV. “We believe the value proposition for single-dose gene editing therapies requires exquisite specificity characterization to ensure safety and efficacy. Today’s presentation highlights the precision of Metagenomi’s next-generation nucleases and ABEs, discovered through the company’s proprietary metagenomics platform and tailored for both in vivo and ex vivo therapeutic applications,” said Alan Brooks, SVP and Head of Preclinical. “MGX-001, Metagenomi’s development candidate for hemophilia A, which utilizes the novel nuclease MG29-1, exhibits no identifiable off-target editing using a series of orthogonal assays employed to evaluate potential off-target sites in the genome. The MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocations in primary human hepatocytes. For Metagenomi’s novel next-generation ABE for ex vivo cell therapy indications via multiplex editing, the data showed no detectable translocations and no significant genomic base composition differences in primary T-cells when compared to unedited cells. These examples demonstrate our strong capabilities in developing highly specific next-generation gene editing tools and support the company’s ability to potentially progress these systems toward the clinic for the benefit of patients.” About Metagenomi Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat associated transposases (CAST)). Metagenomi believes its diverse and modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. For more information, please visit https://metagenomi.co. Cautionary Note Regarding Forward‐Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to conduct IND-enabling studies, make regulatory filings such as INDs, statements concerning the potential of therapies and product candidates, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in “Risk Factors,” in our most recent Form 10-K and our most recent 10-Qs on file with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Contact: Simon Harnest - CIO, SVP Investor Relations IR@metagenomi.coDeluxe ( NYSE:DLX – Get Free Report ) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday. Deluxe Trading Up 1.3 % Shares of DLX opened at $23.24 on Thursday. Deluxe has a 1-year low of $17.60 and a 1-year high of $24.87. The company has a market capitalization of $1.03 billion, a P/E ratio of 18.74, a P/E/G ratio of 0.64 and a beta of 1.46. The company has a debt-to-equity ratio of 2.38, a current ratio of 0.92 and a quick ratio of 0.83. The firm’s 50 day simple moving average is $20.16 and its 200 day simple moving average is $21.14. Insider Buying and Selling In other news, CEO Barry C. Mccarthy purchased 2,820 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was purchased at an average price of $19.08 per share, with a total value of $53,805.60. Following the completion of the purchase, the chief executive officer now directly owns 178,670 shares in the company, valued at approximately $3,409,023.60. This trade represents a 1.60 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link . 4.23% of the stock is owned by company insiders. Hedge Funds Weigh In On Deluxe About Deluxe ( Get Free Report ) Deluxe Corporation provides technology-enabled solutions to enterprises, small businesses, and financial institutions in the United States, Canada, and Australia. It operates through Merchant Services, B2B Payments, Data Solutions, and Print segments. The Merchant Services offers credit and debit card authorization and payment systems, as well as processing services primarily to small and medium-sized retail and service businesses. Further Reading Receive News & Ratings for Deluxe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deluxe and related companies with MarketBeat.com's FREE daily email newsletter .Share Tweet Share Share Email PDF scanner to scan documents, images & text scanner. PDF maker app in premium. PDF scanner app which helps you to get rid of paperwork & digitize your documents to pdf. It is tiny Scanner which helps you to convert images to pdf or photo scan, documents to pdf. PDF scanner give option to make password-protected and give three quality options. Document scanner is pdf maker which help you out to manage your documents safe & securely. PDF Maker app is the ultimate document scanner app that transforms your smartphone into a high-quality, portable document scanner. With Smart Scan capture, edit, convert documents, receipts, notes, ID card, Passport and more into clear sharp PDFs in seconds! Our intelligent auto-cropping, OCR text recognition, and enhanced filters ensure your scans are optimized and easy to read. Perfect for professionals, students, and anyone on the go, its smart scan simplifies document organization and sharing, keeping everything at your fingertips. Features : ☑️ Scan documents with camera scanner ☑️ Fill & Sign document ☑️ Scan QR & create QR ☑️ ID Card Scanner , Passport Scanner ☑️ Photo ID Maker ☑️ Image Scanner ☑️ Text Scanner (OCR) ☑️ Merge PDF’s , Split PDF ☑️ Web to PDF ☑️ PDF Maker with password protected ☑️ Compress PDF files ☑️ Organize documents in folders Free Document Scanner: Easily scan and digitize documents like receipts, invoices, and contracts with precision. Convert scanned files into high-quality PDFs or images instantly. Stay organized and share documents effortlessly, right from your device! Experience the power of smart scanning android app. Extract Text From Image(OCR): Extract text from documents and images with advanced OCR technology. Digitize handwritten notes, printed files, and more into editable, searchable text instantly. Advance Document Editing: Enhance your scans with advanced editing features like magic filters, auto-cropping, and brightness adjustments. Add signatures directly to your documents for a seamless and professional finish. Download Document Scanner – PDF Maker today and streamline your digital documentation! Related Items: Document Scanner , PDF Scanner App Share Tweet Share Share Email Recommended for you How To Choose A Document Scanner For Your Business Comments